The 7 major hyperpigmentation markets reached a value of US$ 3.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 6.6 Billion by 2034, exhibiting a growth rate (CAGR) of 6.38% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2023
|
Forecast Years | 2024-2034 |
Historical Years |
2018-2023
|
Market Size in 2023
|
US$ 3.4 Billion |
Market Forecast in 2034
|
US$ 6.6 Billion |
Market Growth Rate (2024-2034)
|
6.38% |
The hyperpigmentation market has been comprehensively analyzed in IMARC's new report titled "Hyperpigmentation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hyperpigmentation refers to the darkening or discoloration of patches of skin compared to the surrounding areas. It occurs when there is an excess production or accumulation of melanin, the pigment responsible for the color of our skin, eyes, and hair. Some of the common symptoms associated with the ailment include the appearance of brown, gray, or black spots on the face, hands, arms, or other sun-exposed areas. In many cases, hyperpigmentation may be accompanied by itching, redness, inflammation, etc. Diagnosing the condition typically involves a visual examination of the affected skin by a healthcare professional, often a dermatologist. The healthcare provider will assess the size, shape, distribution, and color intensity of the pigmented patches. The doctor may also inquire about the patient's medical history, including any recent skin injuries, exposure to the sun, hormonal changes, etc. In some instances, a Wood's lamp examination can be performed to evaluate the extent of hyperpigmentation and rule out certain conditions. Additionally, a skin biopsy may be recommended to confirm the diagnosis or check for other underlying skin disorders.
The escalating cases of sun exposure that trigger the production of melanin as a natural defense mechanism to protect the skin from ultraviolet radiation damage are primarily driving the hyperpigmentation market. In addition to this, the rising demand for prescription-strength retinoids, such as tretinoin, adapalene, tazarotene, etc., since they increase cell turnover and exfoliate the skin, thereby fading pigmentation, is also bolstering the market growth. Furthermore, the inflating adoption of hydroquinone, which inhibits the enzyme responsible for melanin production and reduces the darkening of the skin, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of non-invasive energy-based devices, such as fractional lasers and radiofrequency devices, for treating post-inflammatory hyperpigmentation is also creating a positive outlook for the market. These tools deliver controlled energy to the skin, stimulating collagen production and improving skin texture and tone. Moreover, the ongoing advancements in transdermal delivery systems, including the introduction of microneedling and nanotechnology, which enhance the penetration of active ingredients through the skin, thereby allowing them to reach the deeper layers where melanin production occurs, are expected to drive the hyperpigmentation market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the hyperpigmentation market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hyperpigmentation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperpigmentation market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current hyperpigmentation marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Market Insights
Epidemiology Insights
Hyperpigmentation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies